Galectin Therapeutics Inc. has released a corporate presentation highlighting its focused pipeline in the development of galectin-based therapeutics for chronic liver diseases and cancer. The company's lead candidate, belapectin, is a galectin-3 inhibitor with Fast Track Designation and patent protection through 2032. Clinical data indicate significant efficacy in patients with MASH cirrhosis, especially those without varices, showing a notable reduction in the development of new varices compared to placebo. Belapectin is also being evaluated in combination with Keytruda for melanoma and head and neck cancer, with encouraging clinical responses reported. The presentation also describes ongoing preclinical efforts to develop oral galectin-3 inhibitors. You can access the full presentation through the link below.